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Low protein levels of Hsp27 have been reported in atherosclerotic plaques. In addition, human studies have
indicated that circulating Hsp27 levels are lower in coronary artery disease patients compared with controls. It
remains, however, unclear whether this applies to other forms of atherosclerotic disease.
Plasma Hsp27 from 280 subjects was examined by ELISA. The cohort included 80 coronary artery disease (CAD), 40
peripheral artery disease (PAD) and 80 abdominal aortic aneurysm (AAA) patients. Eighty elderly subjects, without any
clinical history of vascular diseases, were used as a control group. Receiver operating curve (ROC) and logistic
regression model analysis were performed to evaluate the potential value of Hsp27 as a circulating biomarker.
Patients with atherosclerotic vascular diseases had significantly lower levels of Hsp27 than control subjects (p < 0.001).
Moreover, Hsp27 was significantly lower in CAD patients than other atherosclerotic vascular disease groups (p < 0.001).
There was no difference in Hsp27 levels between the AAA and PAD groups. Using the ROC-generated optimal cut-off
values for Hsp27, logistic regression modeling indicated that low plasma Hsp27 was independently associated with the
presence of multiple forms of atherosclerotic disease.
In conclusion, circulating Hsp27 is significantly lower in patients with multiple forms of atherosclerotic arterial disease.Introduction
Atherosclerosis is a complex inflammatory disease process,
which is the foundation of many vascular diseases (Libby
2002), including coronary artery disease (CAD), peripheral
artery disease (PAD) (Sukhija et al. 2004, Sule et al. 2008)
and abdominal aortic aneurysm (AAA) (Jones 2011).
Although AAA has traditionally been considered to be an
atherosclerotic phenotype, it has several distinctive fea-
tures from that of occlusive atherosclerotic disease. These
include differences in gender distribution, an apparently
protective association with diabetes and a histopathology
characterized by extensive medial atrophy and adventitial
inflammation (Sakalihasan et al. 2005, Jones 2011).
Heat shock proteins are abnormally expressed in a
variety of vascular diseases and are emerging as potential
therapeutic targets (Christians et al. 2012, Henderson and
Pockley 2012). Traditionally heat shock proteins are recog-
nized as intracellular chaperones, yet both in vitro and* Correspondence: greg.jones@otago.ac.nz
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the extracellular domain and circulation (Laudanski et al.
2007, Shields et al. 2011). Regardless of their specific
physiological roles, the presence of detectable protein
levels within the circulation may make heat shock proteins
potential diagnostic biomarkers. Heat shock protein 27
(Hsp2), also known as heat shock protein beta-1, is a
member of the small heat shock protein family, which has
been reported to have cyto-protective, anti-apoptotic, anti-
oxidative and anti-inflammatory activity (Vidyasagar et al.
2012, Acunzo et al. 2014). An association between Hsp27
and atherosclerosis has been suggested, with several re-
ports indicating that the expression of Hsp27 is inversely
correlated with plaque burden in human carotid samples
(Martin-Ventura et al. 2004, Martin-Ventura et al. 2006,
Park et al. 2006, Lepedda et al. 2009). Moreover, in mouse
models, overexpression of Hsp27 appeared to reduce aor-
tic plaque burden and promote features of plaque stability
(Rayner et al. 2009, Cuerrier et al. 2013, Seibert et al.
2013). Finally, cohort studies have suggested that circulat-
ing Hsp27 levels may represent a potential biomarker forpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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detected in patients with both carotid and coronary
atherosclerosis (Martin-Ventura et al. 2004, Seibert et al.
2013). Nevertheless, it remains unclear whether lower
levels of circulating Hsp27 represents a generalizable risk
factor for all forms of atherosclerosis, such as that asso-
ciated with smoking or lipoprotein profile (Jones et al.
2007).
This study therefore aimed to determine the relation-
ship between plasma Hsp27 levels and several distinct
forms of arterial vascular disease, including AAA, CAD
and PAD, to further assess Hsp27 as a potential bio-
marker for atherosclerotic disease.
Methods
Study populations
Vascular disease patients, mainly of White ethnic origin
(>97%), were recruited from the Otago region of New
Zealand and compared with a healthy elderly control
group from the same geographical region. All partici-
pants provided written informed consent, and the study
was undertaken with the approval of the Regional Ethics
Committee. A total of 280 patients were enrolled, in
whom vascular disease status consisted of coronary ar-
tery disease (CAD, n =80), ischemic peripheral arterial
disease (PAD, n =40) and abdominal aortic aneurysm
(AAA, n =80). Elderly controls (Control, n = 80) were
also recruited from the local community as previously
described (Jones et al. 2013). In brief, inclusion criteria
consisting of age >55 years, no previous history of ische-
mic heart disease (including angina pectoris), PAD,
stroke (including transient ischemic attack) and being
currently in good general health. Patients classified as
having CAD all had angiographically proven coronary
artery diameter stenosis of ≥50% in at least one vessel.
The percentage diameter stenosis was visually estimated
as the maximum reduction in the vessel diameter
expressed as a percentage of the angiographically normal
adjacent vessel diameter. Peripheral arterial disease was
defined as a significant stenosis in multiple segments, in-
cluding clinical symptoms such as claudication, rest
pain, or tissue loss. The diagnosis of PAD was confirmed
with a resting ankle-brachial index <0.7, pulse volume
recordings, arteriography, and/or duplex arterial scan.
All AAA patients had a maximum infra-renal aortic
diameter >3 cm and were either undergoing surveillance
(3-5 cm) or on active vascular review awaiting surgical
repair (>5 cm). All other study participants (including
controls) underwent an abdominal ultrasound examin-
ation to identify concurrent AAA, with incidental AAA
being an exclusion criterion for the control group. The
CAD with AAA group represented patients, undergoing
coronary angiography, in whom an incidental observa-
tion of AAA (>3 cm) was made.All study participants completed a questionnaire to as-
certain demographic risk factors, including age, gender,
history of hypertension and hyperlipidemia, and smoking
habits (pack years). EDTA and heparin plasma samples
were collected, centrifuged, separated into aliquots and
frozen at -80oC within 30 minutes. Lipoprotein profiles
and high sensitivity C-reactive (hsCRP) protein measure-
ments were performed as previously described (Jones
et al. 2009). An experienced clinical research technician
assisted participants with questionnaire completion.
Plasma HSP27 measurements
Hsp27 levels was measured in heparin plasma using a
commercial ELISA kit according to the manufacturers
instructions (Abcam, Cambridge, UK, ab108862). The
assay detection range was 0.313- 80 ng/ml. The average
coefficient of variation was <6%.
Statistical analyses
All data is presented as the mean ± SD when normally
distributed, otherwise the median (interquartile range,
IQR) is shown. Statistical analyses were performed using
an ANOVA test for age comparisons between groups
and Mann–Whitney U-test for Hsp27, HDL-cholesterol
and hsCRP comparisons between groups. The chi-
square test was used to compare categorical data be-
tween each group. Receiver operating characteristic
(ROC) curves were constructed to determine the opti-
mal binary cut-off value of Hsp27 to differentiate vascu-
lar patients from elderly controls. This value was
calculated using the maximum of the Youden index J =
max [SEi + SPi-1], where SEi and SPi are the sensitivity
and specificity over all possible threshold values. Differ-
ences were considered significant at p-values <0.05. A
stepwise logistics regression analysis was then performed
to establish if the binary cut-off value for Hsp27 was
significantly associated with the presence of vascular
disease, independent of other confounding variables in-
cluding age, gender, smoking, diabetes, hypertension,
dyslipidemia and hsCRP levels. Analyses were performed
using Statview 5.01 (SAS Institute). The mROC (Unité
de biostatistiques, CRLC Val d’Aurelle, V1.0) software




The characteristics of the study populations are summa-
rized in Table 1. All groups were well-matched for age
and gender. However, smoking pack years and history of
hypertension and dyslipidemia were significantly higher
in all four vascular disease groups compared with the
vascular disease-free control group (p < 0.001). Diabetes
was only significantly different between the control and









Age (years) 72.7 ± 6.1 74.8 ± 8.1 72.1 ± 9.4 75.0 ± 8.6
Males (%) 66 (82.5) 63 (78.8) 32 (80.0) 67 (83.8)
BMI (kg/m2) 25.9 ± 3.5 27.1 ± 4.4 26.3 ± 4.1† 28.5 ± 4.5*
History IHD (%) 0 (0) 35 (43.8)† 12 (30.0)† 80 (100)
Smoking (pack years) 0 (0–12.3) 26.0 (10.0-42.6)* 23.8 (6.9-40.0)* 16.3 (0–33.1)*
Diabetes (%) 5 (6.3) 9 (11.3) 6 (15.0) 17 (21.3)*
Hypertension (%) 25 (31.3) 48 (60.0)* 26 (65.0)* 64 (80.0)*
Dyslipidemia (%) 25 (31.3) 43 (53.8)* 28 (70.0)* 60 (75.0)*
hs-CRP, mg/L 1.9 (1.1-4.7) 1.9 (0.9-5.1)† 2.2 (1.3-5.7) 4.5 (2.3-4.9)*
HDL-C mmol/L 1.22 (1.05-1.49) 1.11 (0.93-1.31)* 1.16 (0.96-1.53) 1.14 (0.93-1.31)
Hsp27, ng/ml 2.68 (1.78-4.42) 1.82 (0.91-3.37)*† 1.93 (1.01-3.05)*† 1.23 (0.84-2.12)*
Age and BMI are shown as mean ± SD; Hsp27 and smoking (pack years) are shown as median (IQR); The categorical data is presented as number (percentage). *p < 0.001
versus control group; †p < 0.001 versus CAD group.
Body mass index (BMI), Ischemic heart disease (IHD), plasma high sensitivity C-reactive protein (hs-CRP), High-density lipoprotein cholesterol (HDL-C), Heat shock
protein-27 (Hsp27).
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group than the control and AAA groups (p < 0.001).
Plasma Hsp27 levels
Plasma Hsp27 was significantly lower in all of the vascular
disease groups compared to the control group (Table 1).
CAD patients had significantly lower Hsp27 than the other
vascular disease groups (p < 0.0001). However, there was
no significant difference in Hsp27 levels between the PAD
and AAA groups. By univariate (inter and intra-group)
analysis, the levels of Hsp27 were not significantly in-
fluenced by other cardiovascular risk factors, including
age, gender, smoking (pack years), diabetes, dyslipidemia,
hypertension and plasma hsCRP.
ROC curves were plotted to identify the optimal
discrimination value for Hsp27 as a binary threshold to
distinguish the various disease groups from controls.
The greatest area under the ROC curve (AUROC) was
achieved by an Hsp27 value of 2.24 ng/mL when com-
paring CAD patients with elderly controls (Table 2), with
an AUROC value of 0.75 (95% CI: 0.67-0.82).
Using the optimal ROC cut-offs for the respective
vascular diseases, Hsp27 was shown to be significantly
associated with CAD, PAD, AAA and the combined ath-
erosclerotic vascular diseases group. These remainedTable 2 Comparison of Hsp 27 ROC curves in different arteria
Patient group Cut-off value (ng/ml) Sen
CAD (n = 80) 2.24
PAD (n = 40) 2.69
AAA (n = 80) 2.75
All arterial disease patients (n = 200) 2.63
Optimal cut-off values were calculated using the Youden index. Area under the recsignificant following adjustment for known cardiovascular
risk factors, including age, gender, smoking pack years,
diabetes, dyslipidemia, hypertension and hsCRP (Table 3).
Potential associations between plasma Hsp27 and sever-
ity of atherosclerotic disease burden was also assessed. In
CAD patients the extent of (single, double or triple vessel)
disease, showed a trend (p = 0.1) towards decreased Hsp27
in patients with triple versus single vessel disease was ob-
served (median Hsp27 levels of 1.35, 1.19 and 1.08 ng/mL
in 1, 2 and 3 vessel disease respectively). Plasma Hsp27
was not correlated with AAA size (rho = 0.05, p = 0.57) or
severity of PAD as assessed by ankle brachial pressure
index (rho = −0.15, p = 0.38). In all vascular disease pa-
tients, no association was observed between the num-
ber of concurrent diseases and plasma Hsp27 (data not
shown). Plasma Hsp27 did not significantly correlate
with circulating levels of hsCRP or HDL-choelsterol
(data not shown).
In order to determine if the intermediate levels of
Hsp27 in the PAD and AAA groups were due to the
presence of sub-groups with concurrent CAD, these
groups were further divided into those with or without a
history of CAD. The presence of concurrent CAD did
not result in any statistical difference in either median
HSP27 (1.88 ng/mL versus 1.86 ng/mL in those with andl disease groups
sitivity (%) Specificity (%) AUROC AUROC 95% CI
0.69 0.67 0.75 0.67-0.82
0.59 0.58 0.62 0.51-0.71
0.58 0.56 0.60 0.50-0.68
0.61 0.60 0.65 0.58-0.71
eiver operating characteristic curve (AUROC).
Table 3 Logistic regression for plasma Hsp27
Group/binary threshold Univariate odds ratio Adjusted* odds ratio
Odds ratio 95% CI P value Odds ratio 95% CI P value
All CAD (n = 80), Hsp27 > 2.24 0.17 0.08-0.34 0.0001 0.21 0.10-0.42 0.0001
PAD (n = 40), Hsp27 > 2.69 0.36 0.16-0.81 0.013 0.25 0.09-0.71 0.009
AAA (n = 80), Hsp27 > 2.75 0.43 0.22-0.82 0.011 0.29 0.12-0.69 0.005
All disease patients (n = 200), Hsp27 > 2.63 0.32 0.18-0.55 0.001 0.21 0.10-0.42 0.001
PAD & AAA (n = 120), Hsp27 > 2.63 0.40 0.22-0.72 0.002 0.26† 0.17-0.56 0.006
Logistic regression analysis was used to calculate the odds ratios for having plasma Hsp27 levels above binary thresholds. The reference population was the
elderly control group. The adjusted model 1* included age, gender, history of hypertension, dyslipidemia, diabetes, smoking (pack years) and high sensitivity
C-reactive protein. Adjusted model 2† included all factors in model 1 plus history of CAD.
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optimal binary threshold of 2.69 ng/mL (69.6% versus
70.3%, with and without respectively, p = 0.87). Logistic
regression analysis also suggested that the lower levels of
Hsp27 observed in AAA and PAD patients remained
significantly different from controls after adjustment for
the presence of concurrent CAD (Table 3).
Discussion
In this study we demonstrated for the first time that
plasma levels of Hsp27 are a potential biomarker for
several distinct atherosclerotic vascular diseases.
Although it has been previously reported that circulating
Hsp27 is significantly lower in both CAD and carotid
stenosis patients compared with control subjects (Martin-
Ventura et al. 2004, Seibert et al. 2013), it was not clear if
such an association existed in other forms of atheroscler-
otic vascular disease, such as PAD and AAA. In this study
Hsp27 was found to be lower in CAD patients consistent
with previous reports, however, we also demonstrated that
Hsp27 was significantly lower in AAA and PAD patients
compared with a group of elderly controls (with no previ-
ous history of cardiovascular diseases). While plasma
Hsp27 appeared to be reduced in all vascular disease
groups, the CAD group had significantly lower levels than
the other disease groups. However, because of the high de-
gree of concurrent CAD within both the AAA and PAD
groups, the low levels of Hsp27 in these two groups could
conceivably be due to a CAD specific Hsp27 effect. Indeed,
the presence of concurrent disease is a significant limita-
tion of this current study design. Although the presence of
AAA was excluded from other vascular disease groups, we
cannot fully discount the interactive effects of concurrent
vascular disease between the case groups. Nevertheless,
sub-analysis suggested that levels of Hsp27 were similar in
AAA and PAD patients regardless of the presence or
absence of concurrent CAD, while logistic regression
appeared to indicate that the significantly lower plasma
Hsp27 levels in AAA and PAD patients (compared with
elderly controls) are independent of concurrent CAD
(Table 3). Our analysis therefore appears to suggest thatlower circulating levels of Hsp27 in arterial disease
patients is not specific to CAD, but rather is a relatively
ubiquitous finding amongst atherosclerotic vascular dis-
ease phenotypes.
To further assess the utility of Hsp27 as a biomarker
for atherosclerotic diseases, we performed ROC analysis
to determine the optimal binary cut-off values to distin-
guish between atherosclerotic cases and controls. The
greatest discrimination was observed when comparing
CAD patients with elderly controls. Using a binary cut-
off value we were able to demonstrate a significant
univariate association with all forms of vascular disease.
This remained as an independent protective association
following adjustment for known risk factors. While these
observations are encouraging, it should be noted that
this study is limited by its retrospective design and
clearly further prospective cohort studies are required to
assess the clinical utility of plasma Hsp27 as a predictor
of (early asymptomatic) atherosclerotic disease.
Nevertheless, our current observation of reduced
plasma Hsp27 in patients with vascular disease appears
to be consistent with previous reports suggesting reduced
Hsp27 levels within atherosclerotic plaques (Martin-
Ventura et al. 2004, Martin-Ventura et al. 2006). Func-
tionally, hsp27 is a known potent anti-apoptotic protein
(Ferns et al. 2006, Ghayour-Mobarhan et al. 2012,
Vidyasagar et al. 2012). Since apoptosis of vascular
smooth muscle is involved in the weakening of the
fibrous cap and therefore plaque rupture, the reduced
expression of protective Hsp27 may favor the formation
of unstable plaque (Ghayour-Mobarhan et al. 2012,
Vidyasagar et al. 2012, Raizman et al. 2013). In addition,
Hsp27 has been implicated as a regulator of tissue in-
flammation, a pivotal process in atherosclerosis (Libby
2002). It has been suggested that Hsp27 can lower the
levels of the inflammatory cytokine IL-1β in macro-
phages and enhance extracellular levels of the anti-
inflammatory cytokine interleukin-10 (IL-10) (De et al.
2000, Rayner et al. 2008). Extracellular Hsp27 can also
attenuate foam cell formation and atherogenesis by down-
regulating NF-κB signaling in macrophages (Raizman et al.
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post-hoc analysis of our data did not find any significant
correlation between circulating Hsp27 and the inflamma-
tory related markers hsCRP or HDL-cholesterol.
Given the consistent reductions in Hsp27 observed
across arterial disease groups it is perhaps surprising
that we did not observe any strong associations between
plasma Hsp27 and either the extent of coronary artery
disease or burden of concurrent disease. Nevertheless, in
this study we did observe a non-significant trend to-
wards lower plasma Hsp27 with increasing severity of
CAD, which appears to be consistent with a study by
Pourghadamyari and colleagues, in which they reported
a significant positive correlation between serum Hsp27
antibodies and severity of CAD (Pourghadamyari et al.
2011).
In conclusion, the findings of this study are consistent
with previous reports indicating that low plasma Hsp27
levels are associated coronary artery disease. In addition,
we demonstrated that other forms of arterial disease,
including both occlusive (PAD) and aneurysmal (AAA)
phenotypes, also have lower levels than healthy elderly
controls. Plasma Hsp27 remained significantly inversely
associated with arterial disease after adjusting for con-
founding risk factors including age, gender, history of
hypertension, dyslipidemia, diabetes, smoking and hsCRP.
Taken together, these observations appear to suggest that
future investigations are warranted in order to determine
if Hsp27 is a useful circulating biomarker for determining
both susceptibility and severity of atherosclerotic disease
burden within a population.
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